Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease
Listen to this summary
The authors investigate the presence and role of glycosylated non-coding small RNAs (glycoRNAs) in metabolic dysfunction-associated steatotic liver disease (MASLD). They find that glycoRNAs are synthesized in human liver tissues and that their expression is significantly reduced in MASLD, linked to decreased levels of key mediators of glycoRNA biosynthesis. The study suggests that restoring glycoRNA biogenesis may mitigate liver injury, highlighting their potential as biomarkers for MASLD.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of hepatology
View all →Jun 24, 2026 · Journal of hepatology
Regression of liver cirrhosis
Jun 22, 2026 · Journal of hepatology
The Hepato-Exposome Axis: How Endocrine Disruptors Hijack Liver Receptors to Drive MASLD
Jun 22, 2026 · Journal of hepatology
Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials
Jun 20, 2026 · Journal of hepatology
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
Jun 18, 2026 · Journal of hepatology
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ
Jun 15, 2026 · Journal of hepatology
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
